aibio
Financings ·
Entera Bio closes $275.0 million private placement at $2.04 a share
BVF Partners-affiliated funds are among the buyers and gain the right to name two directors. Entera says it will use the money to support a Phase 3 study of EB613.
ENTX Entera Bio Ltd.
Entera Bio (ENTX) news ENTX offering news
Latest Entera Bio news
- Financings
Entera Bio sells 7,827,789 units to BVF-affiliated funds at $1.2775 each in private placement
Entera Bio sold 7,827,789 units to funds affiliated with BVF Partners LP at $1.2775 a unit, with the closing on April 2, 2026. The 8-K names no placement agent or bank, and the company's 10-K says its cash covers operations only through the middle of the third quarter of 2026.
- Financings
Entera Bio signs OPKO oral GLP-1/glucagon deal and sells OPKO shares for $8.0 million
OPKO bought 3,685,226 Entera ordinary shares at about $2.17. Entera will hold the money in escrow to fund its 40% share of development costs. Entera can opt out after Phase 1.
- Financings
OPKO Health buys 3,685,226 Entera Bio shares at $2.17 in obesity collaboration
The two companies will hold 60% and 40% ownership interests in an oral GLP-1/glucagon program. Entera says the proceeds will fund its 40% share through Phase 1.
- Financings
Entera Bio adds up to 30,000,000 shares to its at-the-market program
Entera Bio Ltd. nearly used up the 5,000,000 shares first registered with Leerink Partners. The new supplement covers an additional block under the same sales agreement.
What Entera Bio does
Entera Bio Ltd. is a clinical-stage company developing first-in-class oral tablet formats of peptides and protein replacement therapies. It focuses on chronic conditions where frequent injections create a major treatment gap. Its N-Tab platform is designed to stabilize large hydrophilic peptides in the gastrointestinal tract and promote their absorption into the bloodstream. Its most advanced product candidate, EB613, is oral teriparatide, or oral PTH(1-34), being developed as the first oral, osteoanabolic tablet for osteoporosis. EB613 is being developed under a 505(b)(2) application that references Forteo, which the FDA first approved in 2002. The text says EB613 completed a Phase 2, 6-month, 161-patient, placebo-controlled study that met its biomarker and BMD endpoints. The company also reports post-hoc analyses of that Phase 2 trial. Its pipeline additionally includes oral peptides targeting GLP-1/Glucagon and GLP-2.
| Product or program | What it is | Stage |
|---|---|---|
| EB613 | Oral teriparatide tablet for osteoporosis under a 505(b)(2) application | Phase 2 completed |
| Oral GLP-1/Glucagon and GLP-2 peptides | First-in-class oral peptides in the company pipeline |
Entera Bio annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $42,000 | $181,000 |
| Research and development | $6.0 million | $4.5 million |
| Net income (loss) | -$11.4 million | -$9.5 million |
| Cash from operations | -$7.4 million | -$6.8 million |
| Cash and equivalents | $7.1 million | $8.7 million |
Questions about Entera Bio
Has Entera Bio raised money recently?
Our latest story on this, dated Jul 28, 2026: "Entera Bio closes $275.0 million private placement at $2.04 a share". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Entera Bio?
Entera Bio Ltd. trades under the ticker ENTX on NASDAQ.
Where is Entera Bio listed?
Entera Bio Ltd. is listed on NASDAQ.
What is the SEC CIK of Entera Bio?
The SEC Central Index Key (CIK) for Entera Bio Ltd. is 1638097. Its filings are on SEC EDGAR.
How many shares does Entera Bio have outstanding?
173,141,831 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-07.
Which country or territory is Entera Bio listed under?
Our directory records Entera Bio Ltd. under Israel.
What does Entera Bio do?
Our directory classifies Entera Bio Ltd. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Entera Bio?
The ISIN recorded for Entera Bio Ltd. is IL0011429839.
Does aibio.space cover Entera Bio?
aibio.space lists Entera Bio Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Entera Bio incorporated?
SEC records list its state or country of incorporation as L3.
What does Entera Bio develop?
Entera Bio Ltd. is a clinical-stage company developing first-in-class oral tablet formats of peptides and protein replacement therapies. It focuses on chronic conditions where frequent injections create a major treatment gap.
What is EB613 from Entera Bio?
EB613: Oral teriparatide tablet for osteoporosis under a 505(b)(2) application Stage: Phase 2 completed.
What is Oral GLP-1/Glucagon and GLP-2 peptides from Entera Bio?
Oral GLP-1/Glucagon and GLP-2 peptides: First-in-class oral peptides in the company pipeline Stage: stage not stated.
What was Entera Bio's revenue last year?
$42,000 for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is Entera Bio profitable?
Entera Bio Ltd. reported a net loss of $11.4 million for the fiscal year ended Dec 31, 2025, and used $7.4 million of cash in operations, per its annual report to the SEC.
Investor discussion: Entera Bio
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Financings
Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.02,9.01). Source
- Financings
Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source
- Financings
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source
- Financings
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Stock chart
SEC filings and registration
- SEC name
- Entera Bio Ltd.
- CIK
- 1638097
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) (2836)
- US tickers
- ENTX (Nasdaq)
- State or country of incorporation
- L3
- Fiscal year ends
- December 31
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Business address
- KIRYAT HADASSAH, MINRAV BUILDING, JERUSALEM, 9112002
- Phone
- 972-2-532-7151
- Shares outstanding
- 173,141,831 as of 2026-08-03 (10-Q filed 2026-08-07)
Recent filings
Listing details
- Company
- Entera Bio Ltd.
- Ticker
- ENTX
- Listing
- NASDAQ
- Country or territory
- Israel
- Business scope
- Pharmaceuticals: Major
- ISIN
- IL0011429839
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction